A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
← catalyst calendarNCT07268638 · readout ≤ 315 d
Sponsored by Akebia Therapeutics (industry) · AKBA — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
60estimated
Sites
25
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-03 | actual | When the study began enrolling |
| Primary completion | Jun 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Focal Segmental Glomerulosclerosis
Interventions
- Drug: Praliciguat
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in urine protein-to-creatinine ratio (UPCR)
measured Baseline (Day 1) and up to Week 24
Permalink · AKBA's whole pipeline · Catalyst calendar · Every registered study · What changed